Amphastar Pharmaceuticals Files 8-K on Financials
Ticker: AMPH · Form: 8-K · Filed: 2024-08-07T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: AMPH
TL;DR
AMPH dropped an 8-K on Aug 7th detailing financial results - check it for the deets.
AI Summary
Amphastar Pharmaceuticals, Inc. filed an 8-K on August 7, 2024, to report on its results of operations and financial condition, and to file financial statements and exhibits. The filing details Amphastar's financial performance and provides necessary documentation to the SEC.
Why It Matters
This filing provides crucial updates on Amphastar Pharmaceuticals' financial health and operational results, which are important for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any new material events or significant negative news.
Key Players & Entities
- Amphastar Pharmaceuticals, Inc. (company) — Registrant
- August 7, 2024 (date) — Date of Report
- 11570 6th Street, Rancho Cucamonga, California 91730 (address) — Principal Executive Offices
- 909-980-9484 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Amphastar Pharmaceuticals?
The primary purpose of this 8-K filing is to report on Amphastar Pharmaceuticals, Inc.'s results of operations and financial condition, and to file financial statements and exhibits.
On what date was this 8-K filing made?
This 8-K filing was made on August 7, 2024.
What is the principal executive office address for Amphastar Pharmaceuticals?
The principal executive office address for Amphastar Pharmaceuticals is 11570 6th Street, Rancho Cucamonga, California 91730.
What is the telephone number listed for Amphastar Pharmaceuticals?
The telephone number listed for Amphastar Pharmaceuticals is (909) 980-9484.
Under which section of the Securities Exchange Act of 1934 is this Current Report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-08-07 16:22:20
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share AMPH The NASDAQ Stock Mar
Filing Documents
- amph-20240807x8k.htm (8-K) — 43KB
- amph-20240807xex99d1.htm (EX-99.1) — 718KB
- 0001297184-24-000045.txt ( ) — 911KB
- amph-20240807.xsd (EX-101.SCH) — 3KB
- amph-20240807_lab.xml (EX-101.LAB) — 15KB
- amph-20240807_pre.xml (EX-101.PRE) — 10KB
- amph-20240807x8k_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 7, 2024, Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press release, dated August 7, 2024, issued by Amphastar Pharmaceuticals, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 7, 2024 Amphastar Pharmaceuticals, Inc. By: /s/ WILLIAM J. PETERS William J. Peters Chief Financial Officer, Executive Vice President and Treasurer